Atrial fibrillation
Conditions
Interventions
Phase Two: Experimental Group:Using the ICE (Intracardiac Echocardiography) imaging data of patients, apply AI technology for processing. Specific steps include annotation, extraction, learning, and v
Phase Two: Control Group:Using real data recorded during the actual clinical follow-up of patients, calculate the frequency of thrombotic events and AF recurrence.
Phase 1: AI Learning Set Queue Research:Prospectively collect data from 500 patients undergoing non-valvular atrial fibrillation radiofrequency ablation and/or left atrial appendage occlusion under th
Sponsors
The First Hospital of Jilin University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: percutaneous left atrial appendage occlusion: (1) Patients with non-valvular persistent AF; (2) Age>=18 years; (3) CHA2 DS2-VASc score >=2 points; (4) Has-Bled score>=3 points; (5) There are contraindications to the use of warfarin or are unwilling to take warfarin for a long time. radiofrequency ablation: (1) Age>=18 years and <=80 years; (2) Patients diagnosed with non-valvular atrial fibrillation who are to be treated with radiofrequency ablation; (3) The subject understands the purpose and process of the study and is willing to participate in the study, and signs the informed document.
Exclusion criteria
Exclusion criteria: **Percutaneous Left Atrial Appendage Occlusion Procedure:** 1. Atrial fibrillation (AF) complicated by valvular heart disease; 2. Presence of suspected or confirmed thrombus in the left atrium or left atrial appendage detected by pre-procedural transesophageal echocardiography (TEE); 3. Severe heart failure and significant hepatic or renal dysfunction; 4. Acute myocardial infarction; 5. Stroke within the past month. **Radiofrequency Ablation:** 1. Presence of left atrial appendage thrombus detected by pre-procedural transesophageal echocardiography (TEE); 2. Left atrial anteroposterior diameter >60 mm as assessed by pre-procedural transthoracic echocardiography; 3. Presence of structural heart disease, such as atrial septal defect, ventricular septal defect, Tetralogy of Fallot, or transposition of the great arteries; 4. Postoperative structural heart disease following surgical or interventional procedures, such as atrial septal defect repair or mitral valve replacement; 5. Coagulation dysfunction; 6. Recent active bleeding; 7. Refusal to undergo intracardiac echocardiography catheterization or transesophageal echocardiography; 8. Other conditions deemed unsuitable for interventional treatment by researchers, such as fever, uncontrolled heart failure, recent myocardial infarction, stroke or bleeding, or advanced-stage malignancies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Left atrial appendage blood flow velocity;Left atrial appendage structure; | — |
Secondary
| Measure | Time frame |
|---|---|
| Spontaneous contrast in the left atrial appendage; | — |
Countries
China
Contacts
Public ContactShuyan Li
The First Hospital of Jilin University
Outcome results
None listed